 |
BioWorld-International-2006-11-01
CAT's Humira Royalty Sold By AstraZeneca For $700M
CAT's Humira Royalty Sold By AstraZeneca For $700M
LONDON - AstraZeneca plc, the new owner of Cambridge Antibody Technology Group (CAT) Ltd., sold the royalty rights to the antibody company's one marketed product, Humira, for $700 million. (BioWorld International)